Pharmaceutical Technology on MSN14d
ITM targets US approval for radiopharmaceutical after Phase III readout
ITM Isotope Technologies Munich SE is gearing up to enter the US market with its radiopharmaceutical therapy, ITM-11 (177Lu-edotreotide), after promising Phase III trial results showed a significant ...
pharmaphorum12y
Afinitor reduces tumours in rare disease, says Novartis
Novartis has announced that phase 3 clinical trials data published in the Lancet showed significant benefit of its cancer drug, Afinitor (everolimus) in patients with non-cancerous tumours ...
GlobalData on MSN1mon
ITM’s radiotherapeutic beats out standard-of-care in Phase III trial
Patients were randomised to receive ITM-11 with a nephroprotective amino acid solution every three months, or Afinitor 10 mg ...
pharmaphorum8y
Novartis' Afinitor gets new EU cancer use
Afinitor (everolimus) has been approved in the EU for advanced, progressive, non-functional neuroendocrine tumours (NETs) of gastrointestinal and lung origin and is the first oral therapy for this ...